What is the primary reason for the delay of the Lotus Edge™ Aortic Valve System?

The 8-K filing itself does not specify the exact reasons for the delay. It states that the press release (Exhibit 99.1) contains more information. Investors should refer to that press release for specific details on the cause of the delay.

When was the Lotus Edge™ Aortic Valve System originally expected to launch in Europe and the U.S.?

The filing mentions 'previously communicated timelines' but does not provide the original expected launch dates. This information would likely be found in prior company announcements or investor communications referenced in the press release.

What impact might this delay have on Boston Scientific's financial results?

A delay in the launch of a significant product like the Lotus Edge™ Aortic Valve System could impact revenue projections and market penetration strategies for the interventional cardiology segment. The full financial impact will depend on the length of the delay and the market reception upon eventual launch.

Where can I find more detailed information about this announcement?

More detailed information is available in the press release issued by Boston Scientific on November 28, 2017, which is included as Exhibit 99.1 to this Form 8-K filing.

BSX 8-K SEC Disclosure — Nov 29, 2017

Summary

Boston Scientific Corporation (BSX) announced on November 28, 2017, a delay in the previously communicated commercialization timelines for its Lotus Edge™ Aortic Valve System in both Europe and the United States. This news, detailed in a press release filed as an exhibit, is a significant development for investors focused on the company's interventional cardiology segment and its pipeline of innovative medical devices. The delay suggests potential challenges or unforeseen circumstances impacting the product's readiness for market entry. Investors should monitor future communications from Boston Scientific for updated timelines, the underlying reasons for the delay, and any potential financial or competitive implications. The company's forward-looking statements accompanying this announcement caution that actual results could differ materially from expectations.

Key Highlights

1Boston Scientific has delayed the commercialization of its Lotus Edge™ Aortic Valve System.
2The delay impacts launch plans in both Europe and the United States.
3The company filed a press release dated November 28, 2017, detailing this event.
4The announcement was made via an 8-K filing on November 28, 2017.
5The Lotus Edge™ Aortic Valve System is a key product in the company's interventional cardiology portfolio.
6The filing includes a cautionary statement regarding forward-looking statements, indicating potential risks and uncertainties.
7Investors are advised to refer to the full press release (Exhibit 99.1) for more details.

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Nov 29, 2017)

Summary

Key Highlights

Frequently Asked Questions